José Antonio Pérez-Simón

TL;DR: Donor lymphocyte infusion following non-myeloablative Allo-SCT is a valuable strategy for relapsed or persistent disease and there was a trend towards significance for time between transplantation and DLI, and response.

TL;DR: This study shows that, with the exception of chromosome 8, a possible marker of clonal evolution, the numeric chromosome changes are present in nearly all malignant plasma cells (r > 0.84), and two triple combinations of chromosome-specific probes, chromosomes 1 and 9 together with either chromosome 13 or 15, could be a useful marker for detection of residual disease.

TL;DR: Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients.

TL;DR: It is shown for the first time that ROS production is required for megakaryocytic differentiation in K562 and HEL cell lines and also in human CD34+ cells and that this might also be important for in vivo megAKaryocytopoiesis.

TL;DR: RIC allogeneic PBSCT may decrease the risk of dying from an opportunistic infection and reduces the occurrence of CMV infection and disease, and the development of GVHD is an important risk factor for these complications.